On the occasion of Pink October, the month dedicated to the fight against breast cancer, SoftFil® is mobilizing throughout the month to raise awareness of the professions of aesthetic medicine and highlight those who courageously fight this disease.
With more than 80% of its employees being women, SoftFil® naturally turned to the Pink October event to raise awareness about breast cancer. To show their commitment, the teams took part in the Odysséa association’s run and Zumba in solidarity. An opportunity to highlight those who are fighting against this disease, to inform, to raise awareness and to collect funds to support researchers and caregivers.
The main objective of this campaign is to raise awareness of the benefits of early detection of breast cancer. With more than 50,000 new cases each year, breast cancer is the most common and most dangerous cancer in women.
For 13 years, Odysséa Paris has been donating to the Gustave Roussy center, the first European center in the fight against cancer. Last year, thanks to the mobilization of 20.000 participants, more than 507.000€ were collected. Since 2002, more than 5 600 000€ have been redistributed.
Pink October: an indispensable event
Pink October is an event that should not be missed. With more than 50,000 new cases each year, breast cancer is “the most common type of cancer in France and the leading cause of cancer-related death in women,” says the Ligue contre le cancer. If detected, it is imperative to continue the fight against this disease. One woman in eight is likely to develop breast cancer. But that’s not all: a minority of men are also affected by this disease. Thousands of lives are saved every year through early detection.
Today, early detection saves thousands of lives with a cure that can be obtained in more than 9 cases out of 10.
Breast cancer in facts and figures
With 33% of female cancers, breast cancer is the most common cancer among women. In the minority of cases, the development of breast cancer takes several months or even years. Detected early, it is a cancer with a good prognosis, including a standardized net survival rate of 87%. Despite an increase of 0.6% equivalent to 58500 new cases per year between 2010 and 2018, deaths related to this disease have decreased by 1.6% during the same period.
SoftFil is proud of the mobilization of its employees to highlight and raise funds for this important cause.
